Results 301 to 310 of about 369,580 (326)

Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions. [PDF]

Int J Mol Sci
Peshin S, Takrori E, Yazji JH, Haque J, Dharia A, Mithani MS, Anum F, Asfeen U, Couch JK, Donovan M, Singal S.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Development of a degrader against oncogenic fusion protein FGFR3-TACC3

Bioorganic & Medicinal Chemistry Letters, 2022
Fibroblast growth factor receptor 3-transforming acidic coiled-coil containing protein 3 (FGFR3-TACC3), which has been identified in many cancers such as glioblastoma and bladder cancer, is a potent oncogenic fusion protein that induces constitutive activation of FGFR signaling, resulting in uncontrolled cell proliferation.
Norihito, Shibata, Nobuo, Cho, Hiroo, Koyama, Mikihiko, Naito   +3 more
openaire   +2 more sources

Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations

Trends in Cancer, 2017
Pediatric leukemia presents specific clinical and genetic features from adult leukemia but the underpinning mechanisms of transformation are still unclear. Acute megakaryoblastic leukemia (AMKL) is the malignant accumulation of progenitors of the megakaryocyte lineage that normally produce blood platelets. AMKL is diagnosed de novo, in patients showing
Cécile K, Lopez, Sébastien, Malinge, Muriel, Gaudry, Olivier A, Bernard, Thomas, Mercher   +4 more
openaire   +2 more sources

The immune response to oncogenic fusion proteins

2001
Chromosomal translocations represent somatically acquired cytogenetic mutations. When chromosomal breaks occur within exons of two different genes, the consequence of chromosomal translocation is the creation of a new fusion gene encoding for a chimeric protein.
Lorena Passoni, Carlo Gambacorti-Passerini   +1 more
openaire   +1 more source

Abl: the prototype of oncogenic fusion proteins.

Cellular and molecular life sciences : CMLS, 2004
Since it was first recognized, chronic myeloid leukemia (CML) has always represented a unique model to understand the molecular mechanisms underlying the onset and progression of a leukemic process. CML was the first recognized form of cancer to have a strong association with a recurrent chromosomal abnormality, the t(9;22) translocation, which ...
SAGLIO, Giuseppe, CILLONI, Daniela
openaire   +2 more sources

Abstract A68: Posttranslational modifications of the oncogenic fusion protein EWS/FLI1

Cancer Research, 2014
Abstract Ewing sarcoma is a pediatric tumor that affects bone and soft tissues. It is characterized in the majority of cases by the presence of a chromosomal translocation that leads to the expression of the oncogenic transcription factor, EWS/FLI1.
Laura A. Lopez Garcia, Maria E. Gierisch, Beat W. Schäfer   +2 more
openaire   +1 more source

The oncogenic fusion protein EWS/NOR-1 induces transformation of CFK2 chondrogenic cells

Experimental Cell Research, 2004
The EWS/NOR-1 fusion protein is encoded by the t(9;22) chromosomal translocation found in approximately 75% of extraskeletal myxoid chondrosarcoma (EMC) tumors. The lack of cellular models in which the oncogenic properties of this fusion protein are expressed has seriously hampered the study of its role in the development of EMC.
Christine, Filion, Yves, Labelle
openaire   +2 more sources

NAB2-STAT6 fusion protein mediates cell proliferation and oncogenic progression via EGR-1 regulation

Biochemical and Biophysical Research Communications, 2020
Solitary fibrous tumors are rare mesenchymal tumors derived from soft tissues and vascular walls. NAB2-STAT6 fusion gene serves as a marker gene for this disease and consists of the truncated repressor domain of NGFI-A-Binding protein 2 (NAB2) and the intact activation domain of STAT6.
Ye-Seul Park, Hyeng-Soo Kim, Ju-Heon Kim, Sung-Hun Choi, Da-Som Kim, Zae Young Ryoo, Jae-Young Kim, Sanggyu Lee   +7 more
openaire   +2 more sources

Precision Medicine for High-Risk Gene Fusions in Pediatric AML: a focus on KMT2A, NUP98, and GLIS2 Rearrangements.

Blood
Robust genetic characterization of paediatric AML has demonstrated that fusion oncogenes are highly prevalent drivers of AML leukemogenesis in young children.
Grace Egan, S. Tasian
semanticscholar   +1 more source

Abstract 4968: Modes of co-factor recruitment by an oncogenic fusion protein

Cancer Research, 2010
Abstract Ewing's sarcoma (ESFT) is a highly aggressive pediatric cancer of the bone and characterized by the chimeric ETS transcription factor EWS-FLI1 as a result of a chromosomal translocation. By whole genome gene expression and ChIP-seq analyses we obtained evidence that EWS-FLI1 directly regulates E2F target genes and possibly ...
Raphaela Schwentner, Maximilian O. Kauer, Sven Bilke, Gunhild Jug, Robert L. Walker, Paul S. Meltzer, Heinrich Kovar   +6 more
openaire   +1 more source